Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Melanoma 45Carcinoma, Renal Cell 19Neoplasm Metastasis 16Leukemia, Myeloid, Acute 15Kidney Neoplasms 14Skin Neoplasms 11Neoplasms 10Leukemia 7Breast Neoplasms 7Lymphoma, Non-Hodgkin 6Myelodysplastic Syndromes 5Ovarian Neoplasms 4Neuroblastoma 4Congenital Abnormalities 4Colorectal Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Uveal Melanoma 2Prostatic Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Myeloid 1Sarcoma, Ewing 1Sarcoma 1

Interventions

Radiation Dose Hypofractionation 2Immune Checkpoint Inhibitors 2Granulocyte-Macrophage Colony-Stimulating Factor 2envafolimab 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Refractory Solid Tumors × Interleukin-2 × Clear all
NCT04892498 2022-08-09

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
66 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡